UCB PHARMA SA

UCB PHARMA SA logo
🇧🇪Belgium
Ownership
Public, Subsidiary
Established
1928-01-01
Employees
9K
Market Cap
$34.9B
Website
https://www.ucb-iberia.com/home
Clinical Trials
Related News

Clinical Study in Healthy Volunteers to Investigate the Neurocognitive Effects of a New Antiepileptic Drug: Brivaracetam

First Posted Date
2008-08-18
Last Posted Date
2012-05-28
Lead Sponsor
UCB Pharma
Target Recruit Count
20
Registration Number
NCT00736931

CDP323 Biomarker Study

Phase 1
Completed
Conditions
Relapsing Multiple Sclerosis
Interventions
Drug: CDP323
Drug: Placebo
First Posted Date
2008-08-01
Last Posted Date
2011-09-12
Lead Sponsor
UCB Pharma
Target Recruit Count
71
Registration Number
NCT00726648

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis

First Posted Date
2008-07-17
Last Posted Date
2018-08-01
Lead Sponsor
UCB Pharma
Target Recruit Count
1648
Registration Number
NCT00717236

A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures

Phase 3
Terminated
Conditions
Epilepsy
Interventions
Drug: Brivaracetam
First Posted Date
2008-06-17
Last Posted Date
2018-07-11
Lead Sponsor
UCB Pharma
Target Recruit Count
62
Registration Number
NCT00699283

A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures

Phase 3
Terminated
Conditions
Epilepsy
Interventions
Drug: Brivaracetam
First Posted Date
2008-06-17
Last Posted Date
2018-07-11
Lead Sponsor
UCB Pharma
Target Recruit Count
88
Registration Number
NCT00698581

Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study

First Posted Date
2008-05-07
Last Posted Date
2012-01-18
Lead Sponsor
UCB Pharma
Target Recruit Count
194
Registration Number
NCT00674362

Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease

Phase 2
Completed
Conditions
Systemic Lupus Erythematosus
Interventions
Biological: Epratuzumab
First Posted Date
2008-04-17
Last Posted Date
2012-07-12
Lead Sponsor
UCB Pharma
Target Recruit Count
210
Registration Number
NCT00660881

A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis

First Posted Date
2008-04-04
Last Posted Date
2011-08-31
Lead Sponsor
UCB Pharma
Target Recruit Count
580
Registration Number
NCT00653224

Pharmacovigilance Study of Keppra. SPAIN - SKATE : Safety of Keppra as Adjunctive Therapy in Epilepsy

Phase 4
Completed
Conditions
Epilepsy, Partial
First Posted Date
2008-03-26
Last Posted Date
2013-11-15
Lead Sponsor
UCB Pharma
Target Recruit Count
342
Registration Number
NCT00643500

Efficacy and Safety of Cetirizine Tablets Versus Ketotifen Dry Syrup in Children With Perennial Allergic Rhinitis

Phase 3
Completed
Conditions
Rhinitis, Allergic, Perennial
First Posted Date
2008-03-20
Last Posted Date
2009-09-04
Lead Sponsor
UCB Pharma
Target Recruit Count
149
Registration Number
NCT00639587
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy